211 related articles for article (PubMed ID: 17662084)
1. Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.
Zuluaga Toro T; Hsieh FH; Bodo J; Dong HY; Hsi ED
Br J Haematol; 2007 Oct; 139(1):31-40. PubMed ID: 17662084
[TBL] [Abstract][Full Text] [Related]
2. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
3. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
4. Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.
Perbellini O; Zamò A; Colarossi S; Zampieri F; Zoppi F; Bonadonna P; Schena D; Artuso A; Martinelli G; Chilosi M; Pizzolo G; Zanotti R
Cytometry B Clin Cytom; 2011 Nov; 80(6):362-8. PubMed ID: 21656905
[TBL] [Abstract][Full Text] [Related]
5. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.
Baumgartner C; Cerny-Reiterer S; Sonneck K; Mayerhofer M; Gleixner KV; Fritz R; Kerenyi M; Boudot C; Gouilleux F; Kornfeld JW; Sillaber C; Moriggl R; Valent P
Am J Pathol; 2009 Dec; 175(6):2416-29. PubMed ID: 19893034
[TBL] [Abstract][Full Text] [Related]
6. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
8. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
[TBL] [Abstract][Full Text] [Related]
9. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
10. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
11. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
[TBL] [Abstract][Full Text] [Related]
12. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Álvarez-Twose I; Jara-Acevedo M; Morgado JM; García-Montero A; Sánchez-Muñoz L; Teodósio C; Matito A; Mayado A; Caldas C; Mollejo M; Orfao A; Escribano L
J Allergy Clin Immunol; 2016 Jan; 137(1):168-178.e1. PubMed ID: 26100086
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.
Morgado JM; Sánchez-Muñoz L; Teodósio CG; Jara-Acevedo M; Alvarez-Twose I; Matito A; Fernández-Nuñez E; García-Montero A; Orfao A; Escribano L
Mod Pathol; 2012 Apr; 25(4):516-21. PubMed ID: 22222639
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis.
Cherian S; McCullouch V; Miller V; Dougherty K; Fromm JR; Wood BL
Cytometry B Clin Cytom; 2016 Jul; 90(4):387-92. PubMed ID: 26525770
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry.
Baumgartner C; Sonneck K; Krauth MT; Kneidinger M; Födinger M; Hauswirth AW; Müllauer L; Valent P
Eur J Clin Invest; 2008 May; 38(5):326-35. PubMed ID: 18363719
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
Hahn HP; Hornick JL
Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
[TBL] [Abstract][Full Text] [Related]
18. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis.
Berezowska S; Flaig MJ; Ruëff F; Walz C; Haferlach T; Krokowski M; Kerler R; Petat-Dutter K; Horny HP; Sotlar K
Mod Pathol; 2014 Jan; 27(1):19-29. PubMed ID: 23807778
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders.
Sánchez-Muñoz L; Teodósio C; Morgado JM; Escribano L
Methods Cell Biol; 2011; 103():333-59. PubMed ID: 21722810
[TBL] [Abstract][Full Text] [Related]
20. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
